Resverlogix Corp. (RVXCF)

[cabel]

On the latest powerpoint presentation we see on page 17:

2-3 million potential patients for ACS/Diabetes. (that's just one indication,.. other indications have 6 million and 2+ million potential patients!

Sales $6000 annually per patient.

Take just 500,000 patients at $6000 per year = $3 billion

Divided by 200 million shares outstanding (not sure of exact amount fully diluted)

Ball park,... $15 per share revenue (using a multiple of 10 times revenue,.... share price could be $150 per share USD.

There is Zenith to consider etc,... but if the BETonMACE trail is a success by year end,... for the price to get above $20 is a very realistic possiblility

The potential here is immense!